# A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

> **NCT05478031** · PHASE2 · TERMINATED · sponsor: **reMYND** · enrollment: 14 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** REM0046127 High Dose
- **DRUG:** REM0046127 Low Dose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05478031
- **Lead sponsor:** reMYND
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-07
- **Primary completion:** 2024-06-04
- **Final completion:** 2024-06-04
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05478031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05478031, "A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05478031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*